论文部分内容阅读
为了观察小剂量单药化疗对老年晚期非小细胞肺癌(NSCLC)的临床疗效,98例患者接受小剂量多西他赛单药化疗。按照多西他赛20mg/m2剂量加入250mL生理盐水,持续静脉滴入>1.5h,21d为1个周期,化疗>2个周期。参照Karnofsky生存质量评分和实体肿瘤疗效评价标准评定疗效,按照1981年WHO抗癌药物不良反应标准评定不良反应。结果:98例患者,CR1例(1.0%),PR35例(35.7%),SD56例(57.1%),PD6例(6.1%),其中CR+PR36例(36.7%)。治疗前Karnofsky评分为60～90,平均78.46±0.009;治疗后为70～100,平均82.85±0.007。治疗前后差异有统计学意义,t=4.39,P<0.05。初步研究结果提示,小剂量单药化疗减少或避免了不良反应,改善了患者的生活质量,延长了生存时间,应为老年晚期NSCLC的首选治疗方案。
To observe the clinical efficacy of low-dose single-agent chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC), 98 patients underwent single-dose chemotherapy with low-dose docetaxel. In accordance with docetaxel 20mg / m2 dose added 250mL saline, continuous intravenous infusion> 1.5h, 21d for a cycle, chemotherapy> 2 cycles. The curative effect was evaluated according to the Karnofsky quality of life score and the solid tumor evaluation standard. Adverse reactions were evaluated according to the WHO standard of adverse drug reactions in 1981. Results: Of the 98 patients, CR1 (1.0%), PR35 (35.7%), SD56 (57.1%) and PD6 (6.1%) had CR + PR36 cases (36.7%). Karnofsky score before treatment 60 ~ 90, an average of 78.46 ± 0.009; after treatment, 70 to 100, an average of 82.85 ± 0.007. Before and after treatment, the difference was statistically significant, t = 4.39, P <0.05. Preliminary findings suggest that low-dose single-agent chemotherapy reduces or avoids adverse reactions, improves patient quality of life, prolongs survival time, and should be the first-line treatment for advanced NSCLC.